Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company, will be presenting at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company, will be presenting at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available on January 10 at 7:00 AM ET on their website. Imara is focused on developing therapeutics for rare genetic disorders, advancing tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia, and IMR-261 as an Nrf2 activator.
Details
News Market Reaction – IMRA
The recorded move for IMRA in the trading session of this news was -10.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.
A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10th and will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for sickle cell disease and beta-thalassemia and preclinical development for heart failure with preserved ejection fraction, or HFpEF. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.
Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com
Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.